Peter Bramlage
Institute for Cardiovascular Pharmacology and Epidemiology
Mahlow
Germany
Name/email consistency: high
- Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Bramlage, P., Wolf, W.P., Fronk, E.M., Stuhr, T., Erdlenbruch, W., Wasem, J., Ketelhut, R., Schmieder, R.E. Expert. Opin. Pharmacother (2010)
- Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Bramlage, P., Wolf, W.P., Stuhr, T., Fronk, E.M., Erdlenbruch, W., Ketelhut, R., Schmieder, R.E. Vasc. Health. Risk. Manag (2010)
- Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. Bramlage, P., Schindler, C. Expert. Opin. Pharmacother (2010)
- A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. Bramlage, P., Böhm, M., Volpe, M., Khan, B.V., Paar, W.D., Tebbe, U., Thoenes, M. J. Clin. Hypertens. (Greenwich) (2010)
- Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Bramlage, P. Vasc. Health. Risk. Manag (2009)
- Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Bramlage, P. Expert. Opin. Pharmacother (2009)









